0	0	1998-09-23	CD	O	O	B-Num
0	1	20	CD	O	O	B-Num
0	2	:	:	O	O	I-Num
0	3	16	CD	O	B-NP	I-Num
0	4	BAYER	NNP	O	I-NP	B-Org
0	5	TO	TO	O	B-PP	I-Org
0	6	FUND	NNP	O	B-NP	I-Org
0	7	GENOMICS	NNP	O	I-NP	I-Org
0	8	RESEARCH	NNP	O	I-NP	I-Org
0	9	AT	IN	O	I-NP	I-Org
0	10	MILLENNIUM	NNP	O	I-NP	I-Org

1	0	In	IN	O	B-PP	O
1	1	one	CD	O	B-NP	B-Num
1	2	of	IN	O	B-PP	O
1	3	the	DT	O	B-NP	O
1	4	largest	JJS	O	I-NP	O
1	5	alliances	NNS	O	I-NP	O
1	6	ever	RB	O	O	O
1	7	forged	VBD	O	B-VP	O
1	8	in	IN	O	B-PP	O
1	9	the	DT	O	B-NP	O
1	10	field	NN	O	I-NP	O
1	11	of	IN	O	B-PP	O
1	12	drug	NN	O	B-NP	B-Medical
1	13	discovery	NN	O	I-NP	O
1	14	COMMA	COMMA	O	O	O
1	15	Millennium	NNP	O	B-NP	B-Peop
1	16	Pharmaceuticals	NNP	O	I-NP	I-Peop
1	17	Inc.	NNP	O	I-NP	I-Peop
1	18	said	VBD	O	B-VP	O
1	19	Wednesday	NNP	O	B-NP	B-Date
1	20	it	PRP	O	B-NP	O
1	21	will	MD	O	B-VP	O
1	22	receive	VB	O	I-VP	O
1	23	up	IN	O	O	O
1	24	to	TO	O	B-PP	O
1	25	$465	NN	O	B-NP	B-Money
1	26	million	CD	O	I-NP	B-Num
1	27	from	IN	O	B-PP	O
1	28	Germany	NNP	O	B-NP	B-LocCoun
1	29	's	POS	O	B-NP	O
1	30	Bayer	NNP	O	I-NP	B-OrgCorp
1	31	AG	NNP	O	I-NP	I-OrgCorp
1	32	to	TO	O	B-VP	O
1	33	fund	VB	O	I-VP	O
1	34	research	NN	O	B-NP	O
1	35	and	CC	O	O	O
1	36	to	TO	O	B-VP	O
1	37	buy	VB	O	I-VP	O
1	38	a	DT	O	B-NP	O
1	39	stake	NN	O	I-NP	O
1	40	in	IN	O	B-PP	O
1	41	the	DT	O	B-NP	O
1	42	Cambridge	NNP	O	I-NP	B-OrgCorp
1	43	company	NN	O	I-NP	B-OrgCorp
1	44	.	.	O	O	O

2	0	Bayer	NNP	O	O	B-Loc
2	1	COMMA	COMMA	O	O	O
2	2	Germany	NNP	O	B-NP	B-LocCoun
2	3	's	POS	O	B-NP	O
2	4	No.	NN	O	I-NP	O
2	5	2	CD	O	I-NP	B-Num
2	6	chemicals	NNS	O	I-NP	O
2	7	and	CC	O	I-NP	O
2	8	drug	NN	O	I-NP	B-Medical
2	9	manufacturer	NN	O	I-NP	B-ProfTitle
2	10	COMMA	COMMA	O	O	O
2	11	will	MD	O	B-VP	O
2	12	pay	VB	O	I-VP	O
2	13	$368	NN	O	B-NP	B-Money
2	14	million	CD	O	I-NP	B-Num
2	15	over	IN	O	B-PP	O
2	16	five	CD	O	B-NP	B-Num
2	17	years	NNS	O	I-NP	B-Date
2	18	for	IN	O	B-PP	O
2	19	access	NN	O	B-NP	O
2	20	to	TO	O	B-PP	O
2	21	Millennium	NNP	O	B-NP	B-Peop
2	22	's	POS	O	B-NP	O
2	23	drug	NN	O	I-NP	B-Medical
2	24	discovery	NN	O	I-NP	O
2	25	research	NN	O	I-NP	O
2	26	COMMA	COMMA	O	O	O
2	27	which	WDT	O	B-NP	O
2	28	is	VBZ	O	B-VP	O
2	29	based	VBN	O	I-VP	O
2	30	on	IN	O	B-PP	O
2	31	genomics	NNS	O	B-NP	B-Jour
2	32	COMMA	COMMA	O	O	O
2	33	the	DT	O	B-NP	O
2	34	study	NN	O	I-NP	O
2	35	of	IN	O	B-PP	O
2	36	genes	NNS	O	B-NP	O
2	37	and	CC	O	O	O
2	38	their	PP$	O	B-NP	O
2	39	role	NN	O	I-NP	O
2	40	in	IN	O	B-PP	O
2	41	various	JJ	O	B-NP	O
2	42	diseases	NNS	O	I-NP	O
2	43	.	.	O	O	O

3	0	In	IN	O	B-PP	O
3	1	addition	NN	O	B-NP	O
3	2	COMMA	COMMA	O	O	O
3	3	Bayer	NNP	O	B-NP	B-OrgCorp
3	4	will	MD	O	B-VP	O
3	5	become	VB	O	I-VP	O
3	6	Millennium	NNP	O	B-NP	B-Peop
3	7	's	POS	O	B-NP	O
3	8	largest	JJS	O	I-NP	O
3	9	corporate	JJ	O	I-NP	O
3	10	investor	NN	O	I-NP	B-ProfTitle
3	11	COMMA	COMMA	O	O	O
3	12	spending	VBG	O	B-VP	O
3	13	$97	NN	O	B-NP	B-Money
3	14	million	CD	O	I-NP	B-Num
3	15	for	IN	O	B-PP	O
3	16	a	DT	O	B-NP	O
3	17	14	CD	O	I-NP	B-NumPercent
3	18	percent	NN	O	I-NP	I-NumPercent
3	19	stake	NN	O	I-NP	O
3	20	in	IN	O	B-PP	O
3	21	the	DT	O	B-NP	O
3	22	five-year-old	JJ	O	I-NP	O
3	23	Cambridge	NNP	O	I-NP	B-OrgCorp
3	24	COMMA	COMMA	O	O	O
3	25	Mass.	NNP	O	B-NP	O
3	26	company	NN	O	I-NP	B-OrgCorp
3	27	that	WDT	O	B-NP	O
3	28	has	VBZ	O	B-VP	O
3	29	only	RB	O	I-VP	O
3	30	sporadically	RB	O	I-VP	O
3	31	made	VBN	O	I-VP	O
3	32	money	NN	O	B-NP	B-Money
3	33	.	.	O	O	O

4	0	Millennium	NN	O	B-NP	B-Peop
4	1	's	POS	O	B-NP	O
4	2	genomics	NN	O	I-NP	B-Jour
4	3	technology	NN	O	I-NP	O
4	4	sifts	NN	O	I-NP	O
4	5	through	IN	O	B-PP	O
4	6	hundreds	NNS	O	B-NP	B-Num
4	7	of	IN	O	B-PP	O
4	8	thousands	NNS	O	B-NP	B-Num
4	9	of	IN	O	B-PP	O
4	10	proteins	NNS	O	B-NP	O
4	11	COMMA	COMMA	O	O	O
4	12	or	CC	O	O	O
4	13	``	``	O	O	O
4	14	drug	NN	O	B-NP	B-Medical
4	15	targets	NNS	O	I-NP	O
4	16	''	''	O	O	O
4	17	COMMA	COMMA	O	O	O
4	18	that	WDT	O	B-NP	O
4	19	are	VBP	O	B-VP	O
4	20	used	VBN	O	I-VP	O
4	21	to	TO	O	B-VP	O
4	22	identify	VB	O	I-VP	O
4	23	and	CC	O	O	O
4	24	develop	VB	O	B-VP	O
4	25	drugs	NNS	O	B-NP	O
4	26	.	.	O	O	O

5	0	The	DT	O	B-NP	O
5	1	technology	NN	O	I-NP	O
5	2	lets	VBZ	O	B-VP	O
5	3	companies	NNS	O	B-NP	B-OrgCorp
5	4	radically	RB	O	O	O
5	5	speed	VB	O	B-VP	O
5	6	up	IN	O	O	O
5	7	drug	NN	O	B-NP	B-Medical
5	8	discovery	NN	O	I-NP	O
5	9	.	.	O	O	O

6	0	Under	IN	O	B-PP	O
6	1	the	DT	O	B-NP	O
6	2	agreement	NN	O	I-NP	O
6	3	COMMA	COMMA	O	O	O
6	4	Millennium	NNP	O	B-NP	B-Peop
6	5	will	MD	O	B-VP	O
6	6	deliver	VB	O	I-VP	O
6	7	225	CD	O	B-NP	B-Num
6	8	genomics-based	JJ	O	I-NP	O
6	9	proteins	NNS	O	I-NP	O
6	10	over	IN	O	B-PP	O
6	11	the	DT	O	B-NP	O
6	12	next	JJ	O	I-NP	O
6	13	five	CD	O	I-NP	B-Num
6	14	years	NNS	O	I-NP	B-Date
6	15	.	.	O	O	O

7	0	Those	DT	O	B-NP	O
7	1	compounds	NNS	O	I-NP	O
7	2	will	MD	O	B-VP	O
7	3	target	VB	O	I-VP	O
7	4	cardiovascular	JJ	O	B-NP	B-Medical
7	5	diseases	NNS	O	I-NP	O
7	6	COMMA	COMMA	O	O	O
7	7	cancer	NN	O	B-NP	B-Medical
7	8	COMMA	COMMA	O	O	O
7	9	osteoporosis	NN	O	B-NP	B-Medical
7	10	COMMA	COMMA	O	I-NP	O
7	11	pain	NN	O	I-NP	O
7	12	COMMA	COMMA	O	O	O
7	13	liver	NN	O	B-NP	O
7	14	fibrosis	NN	O	I-NP	B-Medical
7	15	COMMA	COMMA	O	O	O
7	16	hematology	NN	O	B-NP	O
7	17	and	CC	O	I-NP	O
7	18	viral	JJ	O	I-NP	B-Medical
7	19	infections	NNS	O	I-NP	O
7	20	.	.	O	O	O

8	0	&	CC	O	O	O
8	1	UR	NNP	O	B-NP	O
8	2	;	:	O	O	O
8	3	&	CC	O	O	O
8	4	LR	NNP	O	B-NP	O
8	5	;	:	O	O	O
8	6	Bayer	NNP	O	B-NP	B-OrgCorp
8	7	COMMA	COMMA	O	O	O
8	8	best	RB	O	B-VP	O
8	9	known	VBN	O	I-VP	O
8	10	for	IN	O	B-PP	O
8	11	its	PP$	O	B-NP	O
8	12	aspirin	NN	O	I-NP	O
8	13	and	CC	O	O	O
8	14	One-a-Day	NNP	O	B-NP	B-Org
8	15	vitamins	NNS	O	I-NP	O
8	16	COMMA	COMMA	O	O	O
8	17	will	MD	O	B-VP	O
8	18	then	RB	O	I-VP	O
8	19	conduct	VB	O	I-VP	O
8	20	extensive	JJ	O	B-NP	O
8	21	testing	NN	O	I-NP	O
8	22	and	CC	O	I-NP	O
8	23	genetic	JJ	O	I-NP	B-Medical
8	24	screening	NN	O	I-NP	O
8	25	to	TO	O	B-VP	O
8	26	find	VB	O	I-VP	O
8	27	lead	JJ	O	B-NP	O
8	28	proteins	NNS	O	I-NP	O
8	29	that	IN	O	O	O
8	30	it	PRP	O	B-NP	O
8	31	could	MD	O	B-VP	O
8	32	develop	VB	O	I-VP	O
8	33	into	IN	O	B-PP	O
8	34	drugs	NNS	O	B-NP	O
8	35	.	.	O	O	O

9	0	Bayer	NNP	O	B-NP	B-OrgCorp
9	1	will	MD	O	B-VP	O
9	2	pay	VB	O	I-VP	O
9	3	royalties	NNS	O	B-NP	O
9	4	to	TO	O	B-PP	O
9	5	Millennium	NNP	O	B-NP	O
9	6	for	IN	O	B-PP	O
9	7	any	DT	O	B-NP	O
9	8	drugs	NNS	O	I-NP	O
9	9	it	PRP	O	B-NP	O
9	10	markets	NNS	O	B-NP	O
9	11	that	WDT	O	B-NP	O
9	12	were	VBD	O	B-VP	O
9	13	identified	VBN	O	I-VP	O
9	14	through	IN	O	B-PP	O
9	15	the	DT	O	B-NP	O
9	16	partnership	NN	O	I-NP	O
9	17	.	.	O	O	O

10	0	Among	IN	O	B-PP	O
10	1	compounds	NNS	O	B-NP	O
10	2	Bayer	NNP	O	B-NP	B-OrgCorp
10	3	does	VBZ	O	B-VP	O
10	4	not	RB	O	I-VP	O
10	5	pursue	VB	O	I-VP	O
10	6	COMMA	COMMA	O	O	O
10	7	Millennium	NNP	O	B-NP	B-Peop
10	8	can	MD	O	B-VP	O
10	9	select	VB	O	I-VP	O
10	10	drug	NN	O	B-NP	B-Medical
10	11	targets	NNS	O	I-NP	O
10	12	for	IN	O	B-PP	O
10	13	its	PP$	O	B-NP	O
10	14	own	JJ	O	I-NP	O
10	15	development	NN	O	I-NP	O
10	16	.	.	O	O	O

11	0	For	IN	O	B-PP	O
11	1	Millennium	NNP	O	B-NP	B-Peop
11	2	COMMA	COMMA	O	O	O
11	3	the	DT	O	B-NP	O
11	4	deal	NN	O	I-NP	O
11	5	is	VBZ	O	B-VP	O
11	6	a	DT	O	B-NP	O
11	7	major	JJ	O	I-NP	O
11	8	coup	NN	O	I-NP	O
11	9	that	WDT	O	B-NP	O
11	10	also	RB	O	O	O
11	11	helps	VBZ	O	B-VP	O
11	12	boost	NN	O	B-NP	O
11	13	genomics	NNS	O	I-NP	B-Jour
11	14	.	.	O	O	O

12	0	The	DT	O	B-NP	O
12	1	Bayer	NNP	O	I-NP	B-OrgCorp
12	2	money	NN	O	I-NP	B-Money
12	3	will	MD	O	B-VP	O
12	4	increase	VB	O	I-VP	O
12	5	Millennium	NNP	O	B-NP	B-Peop
12	6	's	POS	O	B-NP	O
12	7	potential	JJ	O	I-NP	O
12	8	research	NN	O	I-NP	O
12	9	funding	NN	O	I-NP	O
12	10	from	IN	O	B-PP	O
12	11	corporate	JJ	O	B-NP	O
12	12	partners	NNS	O	I-NP	O
12	13	to	TO	O	B-PP	O
12	14	$1	NN	O	B-NP	B-Money
12	15	billion	CD	O	I-NP	B-Num
12	16	COMMA	COMMA	O	O	O
12	17	the	DT	O	B-NP	O
12	18	company	NN	O	I-NP	B-OrgCorp
12	19	said	VBD	O	B-VP	O
12	20	.	.	O	O	O

13	0	``	``	O	O	O
13	1	This	DT	O	B-NP	O
13	2	deal	NN	O	I-NP	O
13	3	helps	VBZ	O	B-VP	O
13	4	us	PRP	O	B-NP	O
13	5	continue	VBP	O	B-VP	O
13	6	our	PP$	O	B-NP	O
13	7	leadership	NN	O	I-NP	O
13	8	in	IN	O	B-PP	O
13	9	drug	NN	O	B-NP	B-Medical
13	10	discoveryCOMMA	NN	O	I-NP	O
13	11	''	''	O	O	O
13	12	said	VBD	O	B-VP	O
13	13	Levin	NNP	O	B-NP	B-Peop
13	14	.	.	O	O	O

14	0	``	``	O	O	O
14	1	For	IN	O	B-PP	O
14	2	Millennium	NNP	O	B-VP	O
14	3	the	DT	O	B-NP	O
14	4	deal	NN	O	I-NP	O
14	5	with	IN	O	B-PP	O
14	6	Bayer	NNP	O	B-NP	B-OrgCorp
14	7	is	VBZ	O	B-VP	O
14	8	phenomenally	RB	O	O	O
14	9	lucrative	JJ	O	O	O
14	10	even	RB	O	O	O
14	11	though	IN	O	O	O
14	12	Bayer	NNP	O	B-NP	B-OrgCorp
14	13	will	MD	O	O	O
14	14	cherry	NN	O	O	O
14	15	pick	VB	O	B-VP	O
14	16	their	PP$	O	B-NP	O
14	17	favcorite	NN	O	I-NP	O
14	18	targetsCOMMA	NN	O	I-NP	O
14	19	''	''	O	O	O
14	20	said	VBD	O	B-VP	O
14	21	Scott	NNP	O	B-NP	B-Peop
14	22	Sacane	NNP	O	I-NP	I-Peop
14	23	COMMA	COMMA	O	O	O
14	24	managing	VBG	O	B-NP	O
14	25	director	NN	O	I-NP	B-ProfTitle
14	26	at	IN	O	B-PP	O
14	27	NationsBanc	NNP	O	B-NP	O
14	28	Montgomery	NNP	O	I-NP	B-LocCit
14	29	Securities	NNPS	O	I-NP	O
14	30	.	.	O	O	O

15	0	For	IN	O	B-PP	O
15	1	Bayer	NNP	O	B-NP	B-OrgCorp
15	2	COMMA	COMMA	O	O	O
15	3	whose	WP$	O	B-NP	O
15	4	prescription	NN	O	I-NP	B-Medical
15	5	pharmaceuticals	NNS	O	I-NP	O
15	6	business	NN	O	I-NP	O
15	7	is	VBZ	O	B-VP	O
15	8	ranked	VBN	O	I-VP	O
15	9	No.	NN	O	B-NP	O
15	10	14	CD	O	I-NP	B-Num
15	11	globally	RB	O	O	O
15	12	COMMA	COMMA	O	O	O
15	13	the	DT	O	B-NP	O
15	14	heavy	JJ	O	I-NP	O
15	15	commitment	NN	O	I-NP	O
15	16	to	TO	O	B-PP	O
15	17	Millennium	NNP	O	B-NP	B-Peop
15	18	is	VBZ	O	B-VP	O
15	19	a	DT	O	B-NP	O
15	20	relatively	RB	O	I-NP	O
15	21	quick	JJ	O	I-NP	O
15	22	_	NN	O	I-NP	O
15	23	and	CC	O	I-NP	O
15	24	expensive	JJ	O	I-NP	O
15	25	_	NN	O	I-NP	O
15	26	way	NN	O	I-NP	O
15	27	to	TO	O	B-VP	O
15	28	regain	VB	O	I-VP	O
15	29	ground	VBN	O	O	O
15	30	lost	VBD	O	B-VP	O
15	31	to	TO	O	B-PP	O
15	32	other	JJ	O	B-NP	O
15	33	large	JJ	O	I-NP	O
15	34	competitors	NNS	O	I-NP	O
15	35	who	WP	O	B-NP	O
15	36	have	VBP	O	B-VP	O
15	37	beefed	VBN	O	I-VP	O
15	38	up	IN	O	O	O
15	39	through	IN	O	B-PP	O
15	40	acquisitions	NNS	O	B-NP	O
15	41	and	CC	O	I-NP	O
15	42	alliances	NNS	O	I-NP	O
15	43	.	.	O	O	O

16	0	Several	JJ	O	B-NP	O
16	1	other	JJ	O	I-NP	O
16	2	genomics	NN	O	I-NP	B-Jour
16	3	companies	NNS	O	I-NP	B-OrgCorp
16	4	have	VBP	O	B-VP	O
16	5	made	VBN	O	I-VP	O
16	6	drug	NN	O	B-NP	B-Medical
16	7	discovery	NN	O	I-NP	O
16	8	deals	NNS	O	I-NP	O
16	9	with	IN	O	B-PP	O
16	10	pharmaceutical	JJ	O	B-NP	B-Medical
16	11	companies	NNS	O	I-NP	B-OrgCorp
16	12	that	WDT	O	B-NP	O
16	13	have	VBP	O	B-VP	O
16	14	averaged	VBD	O	I-VP	O
16	15	only	RB	O	B-NP	O
16	16	$39	NN	O	I-NP	B-Money
16	17	million	CD	O	I-NP	B-Num
16	18	COMMA	COMMA	O	O	O
16	19	according	VBG	O	B-PP	O
16	20	to	TO	O	B-PP	O
16	21	Matthew	NNP	O	B-NP	B-Peop
16	22	N.	NNP	O	I-NP	I-Peop
16	23	Murray	NNP	O	I-NP	I-Peop
16	24	COMMA	COMMA	O	O	O
16	25	a	DT	O	B-NP	O
16	26	senior	JJ	O	I-NP	O
16	27	biotech	JJ	O	I-NP	O
16	28	analysts	NNS	O	I-NP	B-ProfTitle
16	29	at	IN	O	B-PP	O
16	30	Lehman	NNP	O	B-NP	O
16	31	Brothers	NNPS	O	I-NP	O
16	32	.	.	O	O	O

17	0	``	``	O	O	O
17	1	Bayer	NNP	O	B-NP	B-Peop
17	2	is	VBZ	O	B-VP	O
17	3	a	DT	O	B-NP	O
17	4	very	RB	O	I-NP	O
17	5	solid	JJ	O	I-NP	O
17	6	player	NN	O	I-NP	B-ProfTitle
17	7	in	IN	O	B-PP	O
17	8	the	DT	O	B-NP	O
17	9	pharmaceutical	JJ	O	I-NP	B-Medical
17	10	development	NN	O	I-NP	O
17	11	industry	NN	O	I-NP	O
17	12	COMMA	COMMA	O	O	O
17	13	but	CC	O	O	O
17	14	a	DT	O	B-NP	O
17	15	step	NN	O	I-NP	O
17	16	or	CC	O	I-NP	O
17	17	two	CD	O	I-NP	B-Num
17	18	behind	IN	O	O	O
17	19	-LBR-	-LBR-	O	O	O
17	20	in	IN	O	O	O
17	21	-RBR-	-RBR-	O	O	O
17	22	the	DT	O	B-NP	O
17	23	new	JJ	O	I-NP	O
17	24	drug	NN	O	I-NP	B-Medical
17	25	discovery	NN	O	I-NP	O
17	26	technology	NN	O	I-NP	O
17	27	that	IN	O	B-NP	O
17	28	Millennium	NNP	O	B-NP	O
17	29	hasCOMMA	NN	O	I-NP	O
17	30	''	''	O	O	O
17	31	said	VBD	O	B-VP	O
17	32	Sacane	NNP	O	B-NP	B-Peop
17	33	.	.	O	O	O

18	0	``	``	O	O	O
18	1	So	IN	O	O	O
18	2	the	DT	O	B-NP	O
18	3	cost	NN	O	I-NP	O
18	4	of	IN	O	B-PP	O
18	5	being	VBG	O	B-VP	O
18	6	a	DT	O	B-NP	O
18	7	couple	NN	O	I-NP	O
18	8	of	IN	O	B-PP	O
18	9	years	NNS	O	B-NP	B-Date
18	10	late	RB	O	O	O
18	11	and	CC	O	O	O
18	12	the	DT	O	B-NP	O
18	13	cost	NN	O	I-NP	O
18	14	of	IN	O	B-PP	O
18	15	doing	VBG	O	B-VP	O
18	16	business	NN	O	B-NP	O
18	17	with	IN	O	B-PP	O
18	18	the	DT	O	B-NP	O
18	19	best	JJS	O	I-NP	O
18	20	genomics	NN	O	I-NP	B-Jour
18	21	company	NN	O	I-NP	B-OrgCorp
18	22	in	IN	O	B-PP	O
18	23	the	DT	O	B-NP	O
18	24	field	NN	O	I-NP	O
18	25	is	VBZ	O	B-VP	O
18	26	expensive	JJ	O	O	O
18	27	.	.	O	O	O
18	28	''	''	O	O	O

19	0	``	``	O	O	O
19	1	This	DT	O	B-NP	O
19	2	alliance	NN	O	I-NP	O
19	3	is	VBZ	O	B-VP	O
19	4	a	DT	O	B-NP	O
19	5	key	JJ	O	I-NP	O
19	6	strategic	JJ	O	I-NP	O
19	7	move	NN	O	I-NP	O
19	8	which	WDT	O	B-NP	O
19	9	will	MD	O	B-VP	O
19	10	enable	VB	O	I-VP	O
19	11	us	PRP	O	B-NP	O
19	12	to	TO	O	B-VP	O
19	13	develop	VB	O	I-VP	O
19	14	innovative	JJ	O	B-NP	O
19	15	drugs	NNS	O	I-NP	O
19	16	and	CC	O	O	O
19	17	bring	VBP	O	B-VP	O
19	18	them	PRP	O	B-NP	O
19	19	to	TO	O	B-VP	O
19	20	market	VB	O	I-VP	O
19	21	more	RBR	O	O	O
19	22	quickly	RB	O	O	O
19	23	and	CC	O	O	O
19	24	cost-effectivelyCOMMA	JJ	O	O	O
19	25	''	''	O	O	O
19	26	said	VBD	O	B-VP	O
19	27	Horst	NNP	O	B-NP	B-Peop
19	28	Meyer	NNP	O	I-NP	I-Peop
19	29	COMMA	COMMA	O	O	O
19	30	general	JJ	O	B-NP	B-ProfTitle
19	31	manager	NN	O	I-NP	B-ProfTitle
19	32	of	IN	O	B-PP	O
19	33	Bayer	NNP	O	B-NP	B-OrgCorp
19	34	Pharmaceuticals	NNP	O	I-NP	I-OrgCorp
19	35	Business	NNP	O	I-NP	I-OrgCorp
19	36	Group	NNP	O	I-NP	I-OrgCorp
19	37	.	.	O	O	O

20	0	Just	RB	O	B-NP	O
20	1	last	JJ	O	I-NP	O
20	2	week	NN	O	I-NP	O
20	3	COMMA	COMMA	O	O	O
20	4	Bayer	NNP	O	B-NP	B-OrgCorp
20	5	&	CC	O	I-NP	O
20	6	UR	NNP	O	I-NP	O
20	7	;	:	O	O	O
20	8	&	CC	O	O	O
20	9	LR	NNP	O	B-NP	O
20	10	;	:	O	O	O
20	11	announced	VBD	O	B-VP	O
20	12	a	DT	O	B-NP	O
20	13	$1.1	NN	O	I-NP	B-Money
20	14	billion	CD	O	I-NP	B-Num
20	15	deal	NN	O	I-NP	O
20	16	to	TO	O	B-VP	O
20	17	acquire	VB	O	I-VP	O
20	18	the	DT	O	B-NP	O
20	19	diagnostic	JJ	O	I-NP	O
20	20	division	NN	O	I-NP	O
20	21	of	IN	O	B-PP	O
20	22	Chiron	NNP	O	B-NP	B-OrgCorp
20	23	Corp.	NNP	O	I-NP	I-OrgCorp
20	24	COMMA	COMMA	O	O	O
20	25	a	DT	O	B-NP	O
20	26	&	CC	O	I-NP	O
20	27	UR	NNP	O	I-NP	O
20	28	;	:	O	O	O
20	29	&	CC	O	O	O
20	30	LR	NNP	O	B-NP	O
20	31	;	:	O	O	O
20	32	biotechnology	NN	O	B-NP	O
20	33	company	NN	O	I-NP	B-OrgCorp
20	34	based	VBN	O	B-VP	O
20	35	in	IN	O	B-PP	O
20	36	Emeryville	NNP	O	B-NP	B-LocCit
20	37	COMMA	COMMA	O	O	O
20	38	Calif.	NNP	O	B-NP	B-LocStat
20	39	COMMA	COMMA	O	O	O
20	40	in	IN	O	B-PP	O
20	41	an	DT	O	B-NP	O
20	42	effort	NN	O	I-NP	O
20	43	to	TO	O	B-VP	O
20	44	bolster	VB	O	I-VP	O
20	45	its	PP$	O	B-NP	O
20	46	medical	JJ	O	I-NP	O
20	47	products	NNS	O	I-NP	O
20	48	and	CC	O	I-NP	O
20	49	testing	NN	O	I-NP	O
20	50	business	NN	O	I-NP	O
20	51	.	.	O	O	O

21	0	The	DT	O	B-NP	O
21	1	unit	NN	O	I-NP	O
21	2	is	VBZ	O	B-VP	O
21	3	based	VBN	O	I-VP	O
21	4	in	IN	O	B-PP	O
21	5	Waltham	NNP	O	B-NP	B-Loc
21	6	COMMA	COMMA	O	O	O
21	7	Mass	NNP	O	B-NP	B-Loc
21	8	.	.	O	O	O

22	0	That	DT	O	B-NP	O
22	1	acquistion	NN	O	I-NP	O
22	2	came	VBD	O	B-VP	O
22	3	after	IN	O	O	O
22	4	Bayer	NNP	O	B-NP	B-OrgCorp
22	5	announced	VBD	O	B-VP	O
22	6	plans	NNS	O	B-NP	O
22	7	to	TO	O	B-VP	O
22	8	sell	VB	O	I-VP	O
22	9	most	JJS	O	B-NP	O
22	10	of	IN	O	B-PP	O
22	11	its	PP$	O	B-NP	O
22	12	Agfa	NNP	O	I-NP	O
22	13	film	NN	O	I-NP	O
22	14	division	NN	O	I-NP	O
22	15	next	JJ	O	B-NP	O
22	16	year	NN	O	I-NP	O
22	17	in	IN	O	B-PP	O
22	18	a	DT	O	B-NP	O
22	19	public	JJ	O	I-NP	O
22	20	offering	NN	O	I-NP	O
22	21	that	IN	O	B-NP	O
22	22	some	DT	O	B-NP	O
22	23	Wall	NNP	O	I-NP	B-Org
22	24	Street	NNP	O	I-NP	I-Org
22	25	analysts	NNS	O	I-NP	B-ProfTitle
22	26	expect	VBP	O	B-VP	O
22	27	could	MD	O	B-VP	O
22	28	command	VB	O	I-VP	O
22	29	as	RB	O	B-NP	O
22	30	much	JJ	O	I-NP	O
22	31	as	IN	O	B-PP	O
22	32	$4	NN	O	B-NP	B-Money
22	33	billion	CD	O	I-NP	B-Num
22	34	.	.	O	O	O

23	0	Levin	NNP	O	O	B-Peop
23	1	COMMA	COMMA	O	O	O
23	2	who	WP	O	B-NP	O
23	3	expects	VBZ	O	B-VP	O
23	4	the	DT	O	B-NP	O
23	5	deal	NN	O	I-NP	O
23	6	to	TO	O	B-VP	O
23	7	close	VB	O	I-VP	O
23	8	by	IN	O	B-PP	O
23	9	year	NN	O	B-NP	O
23	10	end	NN	O	I-NP	O
23	11	COMMA	COMMA	O	O	O
23	12	said	VBD	O	B-VP	O
23	13	the	DT	O	B-NP	O
23	14	Bayer	NNP	O	I-NP	B-OrgCorp
23	15	money	NN	O	I-NP	B-Money
23	16	will	MD	O	B-VP	O
23	17	enable	VB	O	I-VP	O
23	18	Millennium	NNP	O	B-NP	B-Peop
23	19	to	TO	O	B-VP	O
23	20	become	VB	O	I-VP	O
23	21	profitable	JJ	O	O	O
23	22	for	IN	O	B-PP	O
23	23	the	DT	O	B-NP	O
23	24	year	NN	O	I-NP	O
23	25	and	CC	O	O	O
23	26	increase	VB	O	B-VP	O
23	27	its	PP$	O	B-NP	O
23	28	cash	NN	O	I-NP	O
23	29	on	IN	O	B-PP	O
23	30	hand	NN	O	B-NP	O
23	31	to	TO	O	B-PP	O
23	32	$160	NN	O	B-NP	B-Money
23	33	million	CD	O	I-NP	B-Num
23	34	.	.	O	O	O

24	0	&	CC	O	O	O
24	1	UR	NNP	O	B-NP	O
24	2	;	:	O	O	O
24	3	&	CC	O	O	O
24	4	LR	NNP	O	B-NP	O
24	5	;	:	O	O	O
24	6	Besides	IN	O	B-PP	O
24	7	the	DT	O	B-NP	O
24	8	Bayer	NNP	O	I-NP	B-OrgCorp
24	9	deal	NN	O	I-NP	O
24	10	COMMA	COMMA	O	O	O
24	11	Millennium	NNP	O	B-NP	B-Peop
24	12	's	POS	O	B-NP	I-Peop
24	13	other	JJ	O	I-NP	I-Peop
24	14	partnership	NN	O	I-NP	I-Peop
24	15	deals	NNS	O	I-NP	I-Peop
24	16	total	VBP	O	B-VP	I-Peop
24	17	about	IN	O	B-PP	I-Peop
24	18	$700	NN	O	B-NP	I-Peop
24	19	million	CD	O	I-NP	I-Peop
24	20	COMMA	COMMA	O	O	I-Peop
24	21	with	IN	O	B-PP	I-Peop
24	22	companies	NNS	O	B-NP	I-Peop
24	23	such	JJ	O	B-PP	I-Peop
24	24	as	IN	O	I-PP	I-Peop
24	25	&	CC	O	O	I-Peop
24	26	UR	NNP	O	B-NP	I-Peop
24	27	;	:	O	O	I-Peop
24	28	&	CC	O	O	I-Peop
24	29	LR	NNP	O	B-NP	I-Peop
24	30	;	:	O	O	I-Peop
24	31	Hoffman-La	NNP	O	B-NP	I-Peop
24	32	Roche	NNP	O	I-NP	I-Peop
24	33	COMMA	COMMA	O	O	O
24	34	Eli	NNP	O	B-NP	B-OrgCorp
24	35	Lilly	NNP	O	I-NP	I-OrgCorp
24	36	COMMA	COMMA	O	O	O
24	37	Astra	NNP	O	B-NP	B-OrgCorp
24	38	COMMA	COMMA	O	O	O
24	39	the	DT	O	B-NP	O
24	40	Wyeth-Ayerst	NNP	O	I-NP	B-OrgCorp
24	41	division	NN	O	I-NP	O
24	42	of	IN	O	B-PP	O
24	43	American	NNP	O	B-NP	B-OrgCorp
24	44	Home	NNP	O	I-NP	I-OrgCorp
24	45	Products	NNPS	O	I-NP	I-OrgCorp
24	46	COMMA	COMMA	O	O	O
24	47	Monsanto	NNP	O	B-NP	B-OrgCorp
24	48	and	CC	O	O	O
24	49	Pfizer	NNP	O	B-NP	B-OrgCorp
24	50	&	CC	O	I-NP	O
24	51	UR	NNP	O	I-NP	O
24	52	;	:	O	O	O
24	53	.	.	O	O	O
24	54	&	CC	O	O	O
24	55	LR	NNP	O	B-NP	O
24	56	;	:	O	O	O
24	57	Wednesday	NNP	O	B-NP	B-Date
24	58	Levin	NNP	O	I-NP	B-Peop
24	59	said	VBD	O	B-VP	O
24	60	the	DT	O	B-NP	O
24	61	first	JJ	O	I-NP	B-Num
24	62	drugs	NNS	O	I-NP	O
24	63	from	IN	O	B-PP	O
24	64	these	DT	O	B-NP	O
24	65	partners	NNS	O	I-NP	O
24	66	will	MD	O	B-VP	O
24	67	enter	VB	O	I-VP	O
24	68	pre-clinical	JJ	O	B-NP	O
24	69	or	CC	O	I-NP	O
24	70	animal	NN	O	I-NP	B-Animal
24	71	trials	NNS	O	I-NP	O
24	72	later	RBR	O	O	O
24	73	this	DT	O	B-NP	O
24	74	year	NN	O	I-NP	O
24	75	.	.	O	O	O

25	0	Millennium	NN	O	B-NP	O
25	1	's	POS	O	B-NP	O
25	2	shares	NNS	O	I-NP	O
25	3	Wednesday	NNP	O	B-NP	B-Date
25	4	closed	VBD	O	B-VP	O
25	5	at	IN	O	B-PP	O
25	6	18	CD	O	B-NP	B-Num
25	7	11/16	CD	O	I-NP	B-Num
25	8	COMMA	COMMA	O	O	O
25	9	up	IN	O	O	O
25	10	1	CD	O	B-NP	B-Num
25	11	7/16	CD	O	I-NP	B-Num
25	12	in	IN	O	B-PP	O
25	13	heavy	JJ	O	B-NP	O
25	14	trading	NN	O	I-NP	O
25	15	of	IN	O	B-PP	O
25	16	3.6	CD	O	B-NP	B-Num
25	17	million	CD	O	I-NP	B-Num
25	18	shares	NNS	O	I-NP	O
25	19	.	.	O	O	O

26	0	The	DT	O	B-NP	O
26	1	stock	NN	O	I-NP	O
26	2	has	VBZ	O	B-VP	O
26	3	climbed	VBD	O	I-VP	O
26	4	8	CD	O	B-NP	B-Num
26	5	1/8	CD	O	I-NP	B-Num
26	6	since	IN	O	B-PP	O
26	7	Sept.	NNP	O	B-NP	B-Date
26	8	10	CD	O	I-NP	I-Date
26	9	.	.	O	O	O
